Position
ALGERT GLOBAL LLC in Nurix Therapeutics, Inc.
Back to the book · All holders of NRIX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$178$0.02 → $0.02
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 119.7K | $2.27K | — | — | — | 0.0% |
| Q1 2026 | 51.3K | $796 | $0.02 | −$178 | −$1.3K | 0.0% |